Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential
Authors:
Open Access
- 27 October 2009
- journal article
- Published by SAGE Publications in Journal of the Renin-Angiotensin-Aldosterone System
- Vol. 11 (1) , 75-77
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Angiotensin II Type 2 Receptor StimulationCirculation, 2008
- AT2 receptors: Functional relevance in cardiovascular diseasePharmacology & Therapeutics, 2008
- The AT2 receptor—A matter of love and hatePeptides, 2005
- Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor AgonistJournal of Medicinal Chemistry, 2004
- Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor StimulationCirculation, 2004
- Björn Fokow Award Lecture The angiotensin type 2 receptorJournal Of Hypertension, 1999
- Angiotensin II Induction of Neurite Outgrowth by AT2 Receptors in NG108-15 CellsJournal of Biological Chemistry, 1996
- The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cellsMolecular and Cellular Endocrinology, 1996
- Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in miceNature, 1995
- Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptorNature, 1995